Try our Advanced Search for more refined results

FDA Approval Can't Nix Allergan Patent Obviousness: Sandoz

By Erica Teichert (November 5, 2012, 3:30 PM EST) -- Generic-drug maker Sandoz Inc. urged a Federal Circuit panel on Monday to lift an injunction banning it from marketing a generic version of Allergan Inc.'s glaucoma medication Combigan, saying the lower court overemphasized the importance of U.S. Food and Drug Administration approval and ignored prior art....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!